Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose
Abstract Background Heart failure (HF), the leading cause of morbidity and mortality in the US, affects 6.6 million adults with an estimated additional 3 million people by 2030. More than 50% of HF patients have heart failure with preserved left ventricular ejection fraction (HFpEF). These patients...
Main Authors: | Janet D. Pierce, Diane E. Mahoney, John B. Hiebert, Amanda R. Thimmesch, Francisco J. Diaz, Carol Smith, Qiuhua Shen, Dinesh Pal Mudaranthakam, Richard L. Clancy |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-018-0796-2 |
Similar Items
-
Optimizing the discovery and assessment of therapeutic targets in heart failure with preserved ejection fraction
by: Gabrielle Fusco‐Allison, et al.
Published: (2021-10-01) -
Heart Failure with Preserved Ejection Fraction (HFpEF): A Case Report
by: Amanda Halimi, et al.
Published: (2021-09-01) -
The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
by: Becker Al-Khayatt, et al.
Published: (2024-05-01) -
Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01) -
Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
by: Bin Dong, et al.
Published: (2022-11-01)